Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances
The combination of enfortumab vedotin and pembrolizumab (EVP) has been recently approved for patients with locally advanced and metastatic urothelial carcinoma. This combination showed a higher objective response rate and superior progression-free survival and overall survival over traditional plati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Open Exploration Publishing Inc.
2025-04-01
|
| Schriftenreihe: | Exploration of Targeted Anti-tumor Therapy |
| Schlagworte: | |
| Online-Zugang: | https://www.explorationpub.com/uploads/Article/A1002307/1002307.pdf |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|